

William R Hiatt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1231212/william-r-hiatt-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

4,389
citations

31
h-index

65
g-index

104
ext. papers

5,665
ext. citations

8.8
avg, IF

5.59
L-index

#	Paper	IF	Citations
94	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1768-1778	15.1	3
93	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021 , 16, 841-851	3	1
92	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021 , 235, 12-23	4.9	14
91	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y inhibitors: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021 , 26, 608-612	3.3	
90	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021 , 10, e018684	6	3
89	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3016-3027	15.1	4
88	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 317-326	15.1	6
87	Plantar Flexion-Induced Entrapment of the Dorsalis Pedis Artery in a Teenaged Cross-Country Runner. <i>Annals of Vascular Surgery</i> , 2021 , 70, 213-218	1.7	
86	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. <i>Journal of Medical Economics</i> , 2021 , 24, 402-409	2.4	0
85	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. <i>JACC Basic To Translational Science</i> , 2021 , 6, 174-188	8.7	7
84	Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia: An Analysis From the National Inpatient Sample Database. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007539	5.8	8
83	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e009871	6	
82	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021 , 144, 1104-1116	16.7	2
81	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2772-2780	15.4	0
80	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. <i>Annals of Vascular Surgery</i> , 2021 , 75, 217-226	1.7	1
79	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021 , 1358863X211038620	3.3	0
78	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. <i>Circulation</i> , 2020 , 142, 2219-2230	16.7	17

77	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 866-875	7	27
76	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 3140-3147	15.1	23
75	From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC). <i>Vascular Medicine</i> , 2020 , 25, 103-105	3.3	1
74	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020 , 382, 1994-2004	59.2	248
73	Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 498-508	15.1	24
72	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009326	6	2
71	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006512	5.8	5
70	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016573	6	5
69	Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008069	6	3
68	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 556-565	16.7	37
67	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019 , 50, 1356-1363	6.7	14
66	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019 , 62, 926-938	10.3	65
65	Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1939-1945	14.6	13
64	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. <i>Vascular Medicine</i> , 2019 , 24, 422-430	3.3	7
63	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. <i>JAMA Cardiology</i> , 2019 , 4, 7-15	16.2	18
62	Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. <i>Vascular Medicine</i> , 2018 , 23, 513-522	3.3	1
61	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018 , 199, 83-91	4.9	71
60	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018 , 55, 109-117	2.3	21

59	Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 999-1011	15.1	39
58	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3274-3284	15.1	31
57	Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. <i>Clinical Cardiology</i> , 2018 , 41, 1414-1422	3.3	5
56	Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1563-1572	15.1	23
55	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018 , 206, 80-93	4.9	183
54	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. <i>Circulation</i> , 2017 , 135, 2534-2555	16.7	92
53	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. <i>International Angiology</i> , 2017 , 36, 203-215	2.2	7
52	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 32-40	59.2	339
51	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017 , 135, 241-250	16.7	75
50	Response by Hess and Hiatt to Letter Regarding Article, "A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative". <i>Circulation</i> , 2017 , 136, 2524-2525	16.7	
49	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. <i>Circulation</i> , 2016 , 133, 2459-502	16.7	520
48	Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1338-57	15.1	103
47	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. <i>American Heart Journal</i> , 2016 , 175, 86-93	4.9	36
46	Nonatherosclerotic limb ischemia: Prompt evaluation and diagnosis. <i>Cleveland Clinic Journal of Medicine</i> , 2016 , 83, 741-751	2.8	
45	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. <i>Diabetes Care</i> , 2016 , 39, 738-42	14.6	43
44	Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). <i>Journal of the American College of Cardiology</i> , 2015 , 65, 931-41	15.1	190
43	Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. <i>Circulation Research</i> , 2015 , 116, 1527-39	15.7	86
42	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015 , 169, 486-95	4.9	20

41	Cardiovascular drug development: is it dead or just hibernating?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1567-82	15.1	104
40	The Society for Vascular Medicine: the first quarter century. <i>Vascular Medicine</i> , 2015 , 20, 60-8	3.3	1
39	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Journal of Endovascular Therapy</i> , 2015 , 22, 663-77	2.5	104
38	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Vascular Medicine</i> , 2015 , 20, 465-78	3.3	75
37	An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. <i>Catheterization and Cardiovascular Intervention</i> , 2015 , 96, 511-25	2.7	56
36	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Committee(.). <i>Annals of Vascular Disease</i> , 2015 , 6, 313-57	0.9	99
35	Community-based walking exercise for peripheral artery disease: An exploratory pilot study. <i>Vascular Medicine</i> , 2015 , 20, 339-47	3.3	29
34	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015 , 170, 490-7.e1	4.9	22
33	Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. <i>American Heart Journal</i> , 2014 , 168, 667-73	4.9	18
32	Assessing the clinical benefits of lipid-disorder drugs. <i>New England Journal of Medicine</i> , 2014 , 370, 396-959.2	59.2	11
31	Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. <i>Journal of Vascular Surgery</i> , 2014 , 60, 686-95.e2	3.5	225
30	Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. <i>Vascular Medicine</i> , 2014 , 19, 473-82	3.3	36
29	Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. <i>Vascular Medicine</i> , 2014 , 19, 297-306	3.3	7
28	Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. <i>Circulation</i> , 2014 , 130, 1812-9	16.7	31
27	The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. <i>New England Journal of Medicine</i> , 2013 , 369, 1285-7	59.2	138
26	Cardiovascular risk assessment in the development of new drugs for obesity. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1099-100	27.4	10
25	A validated biomarker panel to identify peripheral artery disease. <i>Vascular Medicine</i> , 2012 , 17, 386-93	3.3	12
24	Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011 , 31, 125-32	3.6	27

23	The Kids-DOTT Trial: Novel Aspects of the Parallel Cohort RCT Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. <i>Blood</i> , 2009 , 114, 4169-4169	2.2	
22	Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. <i>Circulation</i> , 2008 , 117, 2956-7	16.7	9
21	Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. <i>Vascular Medicine</i> , 2006 , 11, 55-60	3.3	22
20	New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. <i>Circulation</i> , 2006 , 113, e394-5	16.7	11
19	Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. <i>Vascular Medicine</i> , 2005 , 10, 207-13	3.3	17
18	The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. <i>Vascular Medicine</i> , 2004 , 9, 271-7	3.3	13
17	Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. <i>Vascular Medicine</i> , 2004 , 9, 18-25	3.3	14
16	Carnitine and peripheral arterial disease. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1033, 92-8	6.5	44
15	Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. <i>Circulation</i> , 2003 , 107, 753-6	16.7	173
14	Pharmacologic therapy for peripheral arterial disease and claudication. <i>Journal of Vascular Surgery</i> , 2002 , 36, 1283-91	3.5	62
13	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. <i>ACP Journal Club</i> , 2002 , 137, 12		1
12	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. <i>ACP Journal Club</i> , 2002 , 137, 12		1
11	Review: Magnetic resonance angiography detects lower-extremity arterial disease in claudication or critical limb ischemia. <i>ACP Journal Club</i> , 2001 , 135, 109		
10	Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. <i>Journal of Applied Physiology</i> , 1999 , 87, 809-16	3.7	72
9	Propionyl-L-Carnitine. <i>Drugs and Aging</i> , 1998 , 12, 0003-0249	4.7	
8	Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. <i>Circulation</i> , 1995 , 91, 1472-9	16.7	346
7	Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 681-92	6.1	58
6	Review: Eblockers do not reduce walking capacity or calf blood flow in peripheral arterial disease. <i>ACP Journal Club</i> , 1992 , 116, 3		

5	Short-term effects of estrogen and progestin on blood pressure of normotensive postmenopausal women. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 543-8	2.9	18
4	Age does not alter human vascular and nonvascular beta 2-adrenergic responses to isoproterenol. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 573-8	6.1	26
3	beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 2-6	6.1	22
2	The effect of platelet protein and DNA on the measurement of human lymphocyte beta adrenergic receptor number. <i>Journal of Receptors and Signal Transduction</i> , 1985 , 5, 419-29		1
1	Selective and nonselective beta-blockade of the peripheral circulation. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 12-8	6.1	16